{
    "Trade/Device Name(s)": [
        "Platelia\u2122 Lyme IgG"
    ],
    "Submitter Information": "Bio-Rad",
    "510(k) Number": "K080012",
    "Predicate Device Reference 510(k) Number(s)": [
        "K894224"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSR"
    ],
    "Summary Letter Date": "April 10, 2008",
    "Summary Letter Received Date": "April 14, 2008",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema pallidum treponemal test reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology",
        "serology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Borrelia burgdorferi"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "K3 EDTA tube",
        "Sodium heparin tube",
        "Sodium citrate tube"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "ELISA",
        "Indirect immuno-enzymatic assay"
    ],
    "Methodologies": [
        "Indirect ELISA"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Bio-Rad Platelia\u2122 Lyme IgG qualitative ELISA assay for detection of IgG antibodies to Borrelia burgdorferi in human serum or plasma",
    "Indications for Use Summary": "Qualitative assay intended for presumptive detection of human IgG antibodies to Borrelia burgdorferi in serum or plasma; positive/equivocal results require confirmation by a specific second-tier test such as Western blot, used in conjunction with clinical assessment.",
    "fda_folder": "Microbiology"
}